Company Filing History:
4 out of 1,975 
3 out of 3,539 
1 out of 78 Years Active: 2011-2013
Title: Teresa Lynn Burgess: Innovator in Cancer Diagnostics and Treatment
Introduction
Teresa Lynn Burgess is a prominent inventor based in Ventura, CA (US). She has made significant contributions to the field of cancer diagnostics and treatment, holding a total of 4 patents. Her innovative work focuses on methods for diagnosing and monitoring cancer progression, as well as developing specific binding agents for hepatocyte growth factor.
Latest Patents
Burgess's latest patents include groundbreaking methods for diagnosing and monitoring the progression of cancer by measuring soluble c-Met ectodomain. These methods provide techniques for measuring c-Met levels in urine and blood samples, which are crucial for cancer diagnosis and prognosis evaluation. Additionally, she has developed specific binding agents that interact with hepatocyte growth factor (HGF). These agents are essential for treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF. Furthermore, her patents describe methods for detecting the amount of HGF in a sample using these specific binding agents.
Career Highlights
Throughout her career, Teresa has worked with notable organizations such as Amgen Inc. and the National Institutes of Health, a component of the US Department of Health & Human Services. Her work in these institutions has allowed her to advance her research and contribute to significant developments in cancer treatment.
Collaborations
Some of her notable coworkers include Donald P. Bottaro and Gagani P. Athauda. Their collaboration has further enhanced the impact of her research in the field.
Conclusion
Teresa Lynn Burgess is a trailblazer in cancer diagnostics and treatment, with a strong portfolio of patents that reflect her innovative spirit. Her contributions continue to influence the medical field and improve patient outcomes.